MAIA Biotechnology Inc. Common Stock (MAIA)
Stock · AMEX · Health Care
$1.1as of 10/16/2026
Price chart
Active signals
Resistance level
$1.3
Industry
Biotechnology: Pharmaceutical Preparations
MAIA Signal Track Record
How signals performed across all stocks →What MAIA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -10.0% | 25% | September 21, 2026 |
| Bollinger Band Breakout | 17 | -5.3% | 41% | June 3, 2026 |
| Bollinger Band Breakdown | 13 | -7.1% | 31% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 6 | +3.0% | 50% | June 4, 2026 |
| Any 20-session window (baseline) | -3.9% | 39% |
Computed by MarketWall from daily closing prices since May 12, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MAIA
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 13
- Website
- maiabiotech.com/
Fundamentals
- 1-day range
- $1.16$1.24
- Market cap
- $86.34M
- P/E (trailing)
- —
- P/E (forward)
- 1.10
- EPS (trailing)
- $-0.64
- Dividend yield
- —
- Beta
- 0.27
- Avg. volume
- 525.8K
52-week range
$0.87$3.19
Next earnings: August 8, 2025 · EPS estimate $-0.25confirmed
Forecasts
2 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$14
+1172.7%
Median
$12
+990.9%
Low
$10
+809.1%
MAIA Biotechnology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MAIAMAIA Biotechnology Inc. Common Stock$1.1▼ 1.79%Market cap $86.34MP/E —$0.87$3.19
- GOSSGossamer Bio Inc. Common Stock$8.77▼ 1.35%Market cap $87.21MP/E —$8.77$309.6
- LFVNLifevantage Corporation Common Stock (Delaware)$6▲ 0.00%Market cap $83.01MP/E 14.40$3.9$11.71
- ATHEAlterity Therapeutics Limited American Depositary Shares$2.62▼ 3.68%Market cap $82.65MP/E —$0.01$0.785
- BMEABiomea Fusion Inc. Common Stock$0.869▲ 3.95%Market cap $90.37MP/E —$0.800501$2.24
- NTHINeOnc Technologies Holdings Inc. Common Stock$2.7▼ 1.82%Market cap $90.77MP/E —$2.5$12
- FBIOFortress Biotech Inc. Common Stock$1.87▼ 2.09%Market cap $92.02MP/E 0.58$1.88$4.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MAIA MAIA Biotechnology Inc. Common Stock | $86.34M | — | $1.1 | ▼ 1.79% | $0.87$3.19 |
| GOSS Gossamer Bio Inc. Common Stock | $87.21M | — | $8.77 | ▼ 1.35% | $8.77$309.6 |
| LFVN Lifevantage Corporation Common Stock (Delaware) | $83.01M | 14.40 | $6 | ▲ 0.00% | $3.9$11.71 |
| ATHE Alterity Therapeutics Limited American Depositary Shares | $82.65M | — | $2.62 | ▼ 3.68% | $0.01$0.785 |
| BMEA Biomea Fusion Inc. Common Stock | $90.37M | — | $0.869 | ▲ 3.95% | $0.800501$2.24 |
| NTHI NeOnc Technologies Holdings Inc. Common Stock | $90.77M | — | $2.7 | ▼ 1.82% | $2.5$12 |
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.58 | $1.87 | ▼ 2.09% | $1.88$4.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Alpha Buying: 4 Biotech Stocks Insiders Are Betting OnBenzinga · 10/8/2026
- MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerYahoo · 10/7/2026
- MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung CancerBenzinga · 10/7/2026
- MAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding AgreementBenzinga · 9/25/2026
- MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and PortugalYahoo · 9/23/2026
- MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung CancerBenzinga · 9/23/2026
- MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung CancerYahoo · 9/22/2026
- MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical TrialYahoo · 9/16/2026
Insider Activity
Insider Actions →Acquired
525.9K
Disposed
0
- Stan Smith · September 30, 2026 · Grant38.9K
- Cristian Luput · September 30, 2026 · Grant33.5K
- Ngar Yee Louie · September 30, 2026 · Grant39.6K
- Guerrero Ramiro · September 30, 2026 · Grant32.0K
- Steven M. Chaouki · September 30, 2026 · Grant32.8K
- Theagene Jean-Manasse · September 30, 2026 · Grant32.0K
- Vlad Vitoc · September 14, 2026 · Buy73.0K @ $1.37
- Guerrero Ramiro · September 10, 2026 · Buy37.6K @ $1.32
- Guerrero Ramiro · August 28, 2026 · Buy46.6K @ $1.35
- Guerrero Ramiro · August 27, 2026 · Buy78.2K @ $1.39
- Guerrero Ramiro · August 26, 2026 · Buy8.9K @ $1.39
- Guerrero Ramiro · August 24, 2026 · Buy1.8K @ $1.33
- Guerrero Ramiro · August 20, 2026 · Buy11.9K @ $1.37
- Guerrero Ramiro · June 30, 2026 · Grant26.4K
- Ngar Yee Louie · June 30, 2026 · Grant32.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 12.91M
- Total value held
- $18.05M
- Institutional holders
- 30
Top holders this quarter
- Unknown4.30M
- Unknown2.50M
- Unknown2.07M
- Unknown1.07M
- Unknown796.7K
- Unknown648.5K
- Unknown500.0K
- Unknown360.5K
- Unknown138.9K
- Unknown128.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
MAIA Expands THIO-104 Trial to Spain, Portugal; Files Resale Prospectus
MAIA Biotechnology has broadened its pivotal Phase 3 THIO‑104 lung‑cancer trial to include Spain and Portugal after receiving regulatory clearance from the Spanish and Portuguese authorities. The company also filed a resale prospectus for 751,879 shares under its Clinical Trial Funding Agreement, providing additional capital for the study. These developments support the trial’s progression and expand patient access in key European markets.
MAIA Expands THIO-104 Trial to Spain, Portugal; Files Resale Prospectus. MAIA Biotechnology has broadened its pivotal Phase 3 THIO‑104 lung‑cancer trial to include Spain and Portugal after receiving regulatory clearance from the Spanish and Portuguese authorities. The company also filed a resale prospectus for 751,879 shares under its Clinical Trial Funding Agreement, providing additional capital for the study. These developments support the trial’s progression and expand patient access in key European markets.